NewsRoom Articles - Page 604 of 1444

ThursdaySep 10, 2020 11:20 am

AIM ImmunoTech Inc. (NYSE: AIM) Featured in Virtual Coverage of The Wall Street Investor Forum

AIM ImmunoTech Inc. (NYSE: AIM) is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers. AIM's flagship products include Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, AIM believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. These and other potential uses will require additional clinical trials to confirm the safety and effectiveness data necessary to support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA being developed…

ThursdaySep 10, 2020 11:20 am

The Wild West Crypto Show Introduces Novel Educational Crypto Card Game

On episode 124, titled “Learn Mining with Card Game,” the hosts of the “Wild West Crypto Show” continued their straight shooting. Drew Taylor and Brent Bates welcomed their first guest, Scott Siblet, who together with his wife has created a novel educational crypto card game. Called SHAmory, the Bitcoin card game was developed to teach those new to crypto about the mining process. There’s no doubt that crypto mining involves abstruse concepts. Siblet hopes that SHAmory will make those ideas more comprehensible. The SHAmory website proclaims the product is the first and only STEM-certified Bitcoin card game. In addition to…

ThursdaySep 10, 2020 11:00 am

TONIX Pharmaceuticals Inc. (NASDAQ: TNXP) Featured in Virtual Coverage of The Wall Street Investor Forum

Tonix Pharmaceuticals Inc. (NASDAQ: TNXP) is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonix's portfolio is primarily composed of central nervous system (CNS) and immunology product candidates. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer and autoimmune diseases. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. For more information, visit the company's website at www.tonixpharma.com To register for The Wall Street Investor Forum and watch the live…

ThursdaySep 10, 2020 10:55 am

The Movie Studio Inc. (MVES) Stands to Benefit as Audiences Return to Cinema Halls in Coming Weeks

Movie theatres across the United States are set to re-open over first half of September Success of OTT platforms during COVID-19 lockdown had led to concerns about future viability of movie theatres Successful launch of ‘Tenet’, a Hollywood spy action thriller released in international markets ahead of its US domestic release, has revealed significant amount of pent-up demand from avid movie goers The Movie Studio is currently engaging in filming process of three major motion pictures Film production companies have been forced into a temporary lull over the past few months, as COVID-19 related restrictions led to wide-ranging cinema closures…

ThursdaySep 10, 2020 10:40 am

Capstone Turbine Corp. (NASDAQ: CPST) Featured in Virtual Coverage of The Wall Street Investor Forum

Capstone Turbine Corp. (NASDAQ: CPST) is the world's leading producer of highly efficient, low-emission, resilient microturbine energy systems. Capstone microturbines serve multiple vertical markets worldwide, including natural resources, energy efficiency, renewable energy, critical power supply, transportation and microgrids. Capstone offers a comprehensive product lineup via its direct sales team, as well as its global distribution network. Capstone provides scalable solutions from 30 kW to 10 MW that operate on a variety of fuels and are the ideal solution for today's multi-technology distributed power generation projects. To date, Capstone has shipped nearly 10,000 units to 83 countries; in FY20, the company…

ThursdaySep 10, 2020 10:20 am

Thunderbird (AMS: TBIRD) Featured in Virtual Coverage of The Wall Street Investor Forum

Through Atomic Cartoons (Kids & Family) and Great Pacific Media (Factual & Scripted), Thunderbird (AMS: TBIRD) is a leader in developing and producing family entertainment and sold to key buyers including Netflix, HBO Max, Nickelodeon, Discovery Channel, Apple TV+, Disney+, NBCUniversal, CBC and traditional broadcast and cable channels in >250 territories globally. Their programs air daily in 40 different languages and include hits such as Beat Bugs, Kim's Convenience, Highway Thru Hell, Blade Runner 2049, Hello Ninja and the Peabody Award winning, Molly of Denali. Thunderbird is a rapidly growing and highly profitable, multi-platform business with FY2019 revenue of $61.5M…

ThursdaySep 10, 2020 10:00 am

LexaGene Holdings Inc. (OTCQB: LXXGF) Featured in Virtual Coverage of The Wall Street Investor Forum

LexaGene Holdings Inc. (OTCQB: LXXGF) is a biotechnology company that develops genetic analyzers for pathogen detection and other molecular markers for on-site rapid testing in veterinary diagnostics and food safety, as well as for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press 'go'. The LX Analyzer delivers excellent sensitivity, specificity and breadth of detection and can return results in about one hour. The unique open-access feature is designed for custom testing so that end-users can load their…

ThursdaySep 10, 2020 9:40 am

Exro Technologies Inc. (OTCQB: EXROF) Featured in Virtual Coverage of The Wall Street Investor Forum

Exro Technologies Inc. (OTCQB: EXROF) is a clean tech company that has developed a new class of control technology for electric powertrains. Exro's advanced motor control technology, 'Coil Driver', expands the capabilities of electric motors and powertrains. The limitations of traditional electric machines and power technology have become more apparent. In many increasingly prominent applications, traditional methods cannot meet the required performance. Exro offers a new solution for system optimization through implementation of the technology, which can yield the following results: increased drive cycle efficiency, reduced system volume, reduced weight and expanded torque and speed capabilities. For more information, visit…

ThursdaySep 10, 2020 9:20 am

Helius Medical Technologies (NASDAQ: HSDT) Featured in Virtual Coverage of The Wall Street Investor Forum

Helius Medical Technologies (NASDAQ: HSDT) is a neurotech company focused on neurological wellness. The company's purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain's ability to heal itself. The company's first product in development is the Portable Neuromodulation Stimulator (PoNS™). Helius was formed as a joint venture between scientists and commercialization experts to address the enormous implications of a massive unmet medical need in the market. For more information, visit the company's website at www.heliusmedical.com To register for The Wall Street Investor Forum and watch the live presentation, visit http://ibn.fm/TWSIFRegistration To view IBN’s…

ThursdaySep 10, 2020 9:00 am

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Featured in Virtual Coverage of The Wall Street Investor Forum

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) develops novel treatments for primary and metastatic cancers of the brain and central nervous system. The company's lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 trial with Berubicin in GBM, which Reata conducted in 2006. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment…

Financial news and publishing for public and private companies

Contact us: 512.354.7000